A phase IIIb trial found that the antimicrobial peptide spray peceleganan (PL-5) significantly improved complete healing and bacterial clearance in mild infected burn wounds without systemic ...

Burn injury disrupts the skin’s primary protective barrier, exposing underlying tissues to a diverse microbial milieu and creating a niche for rapid colonisation and infection. Management begins with ...

A late-stage clinical trial found that a topical spray called peceleganan (PL-5) helped adults with mild infected burn wounds ...

Recce’s R327G highly effective against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa infected wounds (in-vivo) R327G efficacy outcomes statistically significant and ...

A new mouse study shows that non-viable probiotic cells, or paraprobiotics, can suppress bacterial virulence factors and ...

A new Phase IIIb trial found that a synthetic peptide derived from bee and butterfly biology outperformed placebo in healing ...

SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize ...

Hospital-onset bacteremia is common in burn patients—and often tied to burn severity and surgical wound care, not lapses in quality. New data suggest that HOB may be a poor standalone quality metric ...

Discover how wise leadership in infection control transforms challenges into opportunities, fosters teamwork, and safeguards patient safety through emotional intelligence, strategic vision, and ...

A late-stage clinical trial found that a topical spray called peceleganan (PL-5) helped adults with mild infected burn wounds heal better than ...